Kristie L. Kahl

The Food and Drug Administration approved Pemazyre for the treatment of patients with previously treated, advanced cholangiocarcinoma.

In this special edition of the “CURE Talks Cancer” podcast, we teamed up with our sister publication “OncLive on Air” to speak with a patient-doctor duo on myeloproliferative neoplasms.

The Food and Drug Administration approved the combination use of Braftovi plus Erbitux for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation.

The Food and Drug Administration approved the first and only erythroid maturation agent to treat patients with MDS who require red blood cell transfusions and have failed an erythropoiesis stimulating agent.

Patients with relapsed or refractory CD19-positive cancers experienced complete responses with no major side effects following treatment with CAR-NK cell therapy.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Angela Nicholas about her journey as a caregiver to her husband, who was diagnosed with colorectal cancer at 45, and why earlier screening is so vital.

Small cell lung cancer often becomes resistant to chemotherapy, and recent research highlights that these cells evolve, explaining why patients require further lines of treatment.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Aki Smith, founder of Hope for Stomach Cancer, about her journey as her father’s caregiver and what she hopes the organization offers for others affected by a stomach cancer diagnosis.

Jeffrey Glen Jones – an American illustrator who started doing comic books about 25 years ago – is using his creative talents to illustrate the stories of those impacted by MPNs, as part of a campaign called Rare Reflections: MPNs Unmasked.

At the 37th Annual Miami Breast Cancer Conference, Dr. Valerie Lemaine discussed the signs and symptoms of BIA-ALCL, as well as how the disease is diagnosed and treated.

At CURE’s Educated Patient Breast Cancer Summit, Stephanie Seban shared the ways a patient can become their own best advocate to thrive through their breast cancer journey.

“A person becomes a survivor from the point they are diagnosed and for the balance of their lives,” Dr. Don S. Dizon said in a presentation at the 37th Annual Miami Breast Cancer Conference®.

At the 37th Annual Miami Breast Cancer Conference, Dr. Kevin S. Hughes discussed genetic testing and what health care providers should be doing to identify more individuals at risk for cancer.

Xentuzumab in combination with Verzenio, with or without endocrine therapy, may be safe and effective in treating patients with solid tumors and advanced breast cancer.

Premenopausal women with HR-positive, HER2-negative advanced breast cancer experienced improved survival and quality of life with the addition of Kisqali to Zoladex and endocrine therapy to their treatment regimen.

Women who had contralateral prophylactic mastectomy reported similar breast satisfaction and quality of life, cancer-related distress and anxiety and depression scores, compared with those who did not undergo the procedure.

In this episode of the “CURE Talks Cancer” podcast, we spoke with the co-chair of the MMRF’s Laugh for Life event, as well as this year’s “Spirit of Hope” award recipient.

Here is a list of the recent trial initiations that occurred within the cancer space in February.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Andrew Ciupek, from the Go2 Foundation for Lung Cancer, on the importance of biomarker testing and targeted therapy options for patients with non-small cell lung cancer.

MK-6482 demonstrated an objective response rate of 24% among patients with advanced clear cell renal cell carcinoma, according to study findings presented at the 2020 Genitourinary Cancers Symposium.

The Food and Drug Administration granted a priority review to the new drug application for lurbinectedin to treat patients with small cell lung cancer.

After five years of follow-up, treatment with Opdivo in those with previously treated advanced or metastatic renal cell carcinoma induced superior survival outcomes.

More than 50% of patients with previously untreated advanced or metastatic renal cell carcinoma were alive at 42 months after being treated with Opdivo plus Yervoy.

The combination of Padcev plus Keytruda induced a high rate of durable objective response rates in patients with locally advanced or metastatic urothelial cancer.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Bishoy Tadros, who went on to break barriers after he was diagnosed with acute lymphoblastic leukemia at the age of 3 and immigrated to the United States from Egypt to receive treatment.

The Food and Drug Administration granted a priority review to KTE-X19 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Study findings showed that eradicating Helicobacter pylori infection reduced the risk of developing gastric cancer by 73% in those with a first-degree relative with the disease, compared with individuals in whom infection was persistent.

In this episode of the “CURE Talks Cancer” podcast, we spoke with a survivor on two very rare types of cancer, called pheochromocytoma and paraganglioma, and why more research behind these two diseases can help put together the pieces of the cancer puzzle.

Older survivors face increased symptom burden, which in turn affects their well-being, highlighting the need for cancer-related symptom surveillance and intervention.

The refinement of surgical treatment of cancer was named the American Society of Clinical Oncology’s advance of the year, according to its Annual Report on Progress Against Cancer.